Cost-Effectiveness Evaluation of Etoricoxib versus Celecoxib and Nonselective NSAIDs in the Treatment of Ankylosing Spondylitis in Norway

Table 6

Cost-effectiveness of etoricoxib relative to other interventions when anti-TNFα costs are set to zero.

	Incremental costs in NOK			Incremental QALYs			ICER
	Estimate	95% CrI		Estimate	95% CrI		Estimate	95% CrI
1 year
Etoricoxib (90 mg) versus celecoxib (200 & 400 mg)	−337	−410	−280	0.06	0.03	0.10	Dominant	Dominant	Dominant
Etoricoxib (90 mg) versus diclofenac	2,965	2,756	3,173	0.05	0.02	0.09	59,288	33,190	188,200
Etoricoxib (90 mg) versus naproxen	3,663	3,099	4,043	0.03	0.01	0.07	107,074	50,970	488,500
5 years
Etoricoxib (90 mg) versus celecoxib (200 & 400 mg)	2,194	426	3,745	0.20	0.08	0.33	10,926	2083	30820
Etoricoxib (90 mg) versus diclofenac	10,560	9,058	11,880	0.17	0.05	0.30	62,411	34650	198400
Etoricoxib (90 mg) versus naproxen	12,370	10,330	14,000	0.12	0.02	0.23	103,083	49220	465100
30 years
Etoricoxib (90 mg) versus celecoxib (200 & 400 mg)	15,740	5,398	25,490	0.51	0.25	0.84	31,009	14330	59810
Etoricoxib (90 mg) versus diclofenac	23,910	14,520	32,990	0.45	0.20	0.76	53,181	34020	103800
Etoricoxib (90 mg) versus naproxen	25,660	16,150	34,810	0.36	0.13	0.66	70,825	42830	170900